CSL Limited (CMXHF) Stock: Price, Forecast & Analyst Target
CSL Limited (CMXHF) — price $127.68 (+0.14%), as of the Oct 5, 2026 trading session; market cap $61.7B.
Educational signal · not a buy or sell recommendation · How to read this
CSL Limited · CMXHF · Healthcare · Biotechnology
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.
Price as of Oct 5, 2026
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $127.68 |
| Change on the day | +0.14% |
| 52-week range | $63.84–$148.36 |
| Market capitalisation | $61.7B |
| Price / earnings (trailing) | 24.08 |
| Shares traded on the day | 13 |
| Beta (volatility vs the S&P 500) | 0.08 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for CSL (CMXHF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 11, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 6, 2026, except a card that shows its own read date.
Watch the CMXHF film — every key number, told as a short cinematic story
~2 min · open the film
What is CSL (CMXHF), and what does it report?
Short answer · as of
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. CSL Limited (CMXHF) is classified as Healthcare / Biotechnology. Headquarters: 655 Elizabeth Street, Melbourne, VIC, 3000, Australia. It employs 29,000 people and is led by Gordon Naylor DipCompSc. In Q4 FY2026 it reported revenue of $7.30B and net income of -$2.93B. The market values it at $61.7B.
What do the latest results show for CSL (CMXHF)?
Short answer · as of
The most recent reported quarter, Q4 FY2026, carried revenue of $7.30B. Against analyst estimates the company has EPS beat 3 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2026 | $7.30B | -$2.93B | -$6.13 (diluted) |
| Q2 FY2026 | $8.44B | $408M | $0.84 (diluted) |
| Q4 FY2025 | $7.26B | $1.03B | $2.12 (diluted) |
| Q2 FY2025 | $8.21B | $2.01B | $4.13 (diluted) |
What are the financial strengths and risks for CSL (CMXHF)?
Short answer
Cash and short-term investments were $0.00 at the Jun 30, 2026 balance-sheet date. This figure does not establish a cash runway. The distress and quality screens read Altman Z 4.65 · Piotroski F 8. Trailing ratios: ROE 7.6% · ROA 3.8% · current ratio 2.57 · earnings yield 4.2% · free-cash-flow yield 9.3%.
What should you watch next at CSL (CMXHF)?
Short answer · as of
Current published price targets run low $213.00 · high $213.00 · consensus $213.00 · median $213.00 against a quoted price of $127.68 (as of Oct 5, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $213.00 – $213.00
- Consensus target
- $213.00
- Median target
- $213.00
Consensus record · Captured .
Measured against a quoted price of $127.68 (as of Oct 5, 2026).
CMXHF Healthcare Stock FAQ
These answers are editorial: 1 of these 8 answers is drawn from the CMXHF research dossier (written Mar 17, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is CMXHF a good stock to buy?
Stock Expert AI does not rate CMXHF buy, sell or hold. CSL Limited has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the CMXHF stock price today?
The last price recorded on this page for CSL Limited (CMXHF) is $127.68, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the CMXHF price target?
The analyst consensus price target for CSL Limited (CMXHF) is $213.00 (range $213.00 to $213.00, median $213.00), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the main risks for CMXHF?
The main risks for CMXHF include changes in regulatory requirements, competition from other biotechnology companies, economic downturns, and supply chain disruptions. These risks could negatively impact CSL's financial performance and stock price.
What are the key factors to evaluate for CMXHF?
Evaluate CMXHF on fundamentals, analyst consensus, and risk factors. P/E: 24.08x. Analysts target $213.00 (+67%). Not financial advice.
How frequently does CMXHF data refresh on this page?
CMXHF's price is the last quote we recorded, from the Oct 5, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven CMXHF's recent stock price performance?
CSL Limited (CMXHF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Leading position in plasma-derived therapies and influenza vaccines. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CMXHF overvalued or undervalued right now?
CSL Limited (CMXHF) trades at 24.08x earnings. Analysts target $213.00 (+67%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (28 figures)
The 28 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 24 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $127.68 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T21:55:03.204Z. | |
px.change | Change on the day | +0.14% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalization | $61.7B | FMP | Financial Modeling Prep (FMP) quote — Provider market cap uses the share class it prices; a company with more than one class may show a larger total elsewhere. Market cap record date: 2026-10-05. Source capture time was not supplied. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
id.business_summary | Business description (FMP excerpt) | CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | +$0.1824 | FMP | Financial Modeling Prep (FMP) · quote | |
px.range52 | 52-week range | $63.84–$148.36 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 24.08 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 13 | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.08 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Biotechnology | FMP | Financial Modeling Prep (FMP) company profile | |
id.hq | Headquarters | 655 Elizabeth Street, Melbourne, VIC, 3000, Australia | FMP | Financial Modeling Prep (FMP) company profile | |
id.employees | Employees | 29,000 | FMP | Financial Modeling Prep (FMP) company profile | |
fin.q_revenue | Revenue, Q4 FY2026 | $7.30B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q4 FY2026 | -$2.93B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY1970 through FY2026: FY1970 revenue $0.00, net result $0.00; FY2023 revenue $0.00, net result $0.00; FY2024 revenue $0.00, net result $0.00; FY2025 revenue $0.00, net result $0.00; FY2026 revenue $0.00, net result $0.00 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.gross_margin | Gross margin (trailing twelve months) | 51.1% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table | Quarterly income statement | 4 quarters through Q4 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. The market-value ratio is undefined when the reported amount is zero. | |
fin.total_debt | Total debt | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 4.16× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
earn.pt | Stored analyst price targets | low $213.00 · high $213.00 · consensus $213.00 · median $213.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_range | Analyst price target, low to high | $213.00 – $213.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $213.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $213.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied |
UNRECORDED — 4 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.ceo | Chief executive | Gordon Naylor DipCompSc | UNRECORDED | Stored company-profile observation — Captured 2026-10-05 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 3 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-05 | |
fin.scores | Distress and quality screens | Altman Z 4.65 · Piotroski F 8 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-03 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 7.6% · ROA 3.8% · current ratio 2.57 · earnings yield 4.2% · free-cash-flow yield 9.3% | — | UNRECORDED | Stored key metrics — Date unknown |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.